Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro CNBCEli Lilly lifts sales view by $2 billion on soaring weight-loss drug demand Yahoo FinanceLilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues The HillEli Lilly Stock Jumps After It Signals Rise in Obesity and Diabetes Drugs Production The Wall Street JournalLilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | Eli Lilly and Company Investors | Eli Lilly and Company